The U.S. Securities & Exchange Commission published a statement following a jury verdict in the U.S. District Court for the Southern District of California finding Thomas F. Casey liable for securities fraud after a five-day trial. According to the SEC, the fraudulent securities offering targeted retirees’ retirement accounts and induced more than 200 people to invest over USD 10 million in Golden Genesis, described as a venture to create blood banks to sell human plasma from young donors for anti-aging treatments. The offering allegedly relied on false claims that investors would receive guaranteed high returns and that the investments were secured by company assets; the SEC said the funds were not secured and were used to compensate Casey and to pay other investors, resulting in approximately USD 8 million in losses.